Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (66.7%)
Phase 41 (33.3%)

Trials by Status

completed250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_4

Stanford Pragmatic Effectiveness Comparison

NCT04441034
recruiting

Neurobiological and Genomic Predictors of Relapse in Depression

NCT07328373
completedphase_2

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
completedphase_2

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690

Clinical Trials (4)

Showing 4 of 4 trials
NCT04441034Phase 4

Stanford Pragmatic Effectiveness Comparison

Recruiting
NCT07328373

Neurobiological and Genomic Predictors of Relapse in Depression

Recruiting
NCT04437485Phase 2

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Completed
NCT02458690Phase 2

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4